ClinicalTrials.gg
CompletedNCT00237224Updated Nov 19, 2009

Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole

A Phase 4 interventional study of Letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Mexico. Open to female participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-11-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
45 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
111th of 159
40 · median 95
Started
2003
with 6 others
Phase 4
17 of 162
2 open now
Registered
18th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 111th largest by enrollment of the 159 interventional ones that give a count, is one of 7 that started in 2003, is one of 17 in phase 4, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 45 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

To evaluate safety and efficacy (measured by clinical tumor response) of letrozole daily dose, 2.5 mg in postmenopausal patients with primary (untreated) breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer, ER and/or PgR positive, Letrozole
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. woman able to comply with the protocol requirements with primary invasive breast cancer, confirmed by core needle , whose tumors are estrogen (ER) and / or progesterone (PgR) positive, defined by core biopsy immunohistochemistry with > 10% positive malignant epithelial cells.
  2. Clinical stage *T2, T3, T4a,b,c, N0, 1 or 2, M0

    • Clinical stage T2 tumors which in the Investigators opinion would not be eligible for breast-conserving surgery.
  3. Post menopausal status defined by one of the following:

    • No spontaneous menses for at least 1 year, in women > 55 years.
    • Spontaneous menses within the past 1 year but amenorrhoeic in women ≤ 55 years (e.g. spontaneous or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (LH y FSH levels > 40 IU/L) or postmenopausal estradiol levels (\< 5 ng/dl) or according to the definition of "postmenopausal range" for the laboratory involved.
    • Bilateral oophorectomy. (Prior to the diagnosis of breast cancer).
  4. Tumor measurable by clinical examination, mammography and ultrasound.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with letrozole or tamoxifen.
  2. Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or hyperthyroidism, Cushing's Syndrome, Addison's disease (treated or untreated).
  3. Patients with unstable, angina, or uncontrolled cardiac disease (e.g. Class III or IV 's Functional Classification).
  4. Patients with bilateral breast tumors
  5. Patients who are eligible for breast conserving surgery
  6. Evidence of inflammatory breast cancer or distant .

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    FEM345

    Drug: Letrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Identify Eg and/or Pg receptors in breast cancer patients in adjuvant treatment with tamoxifen for 4-5 years

    Time frame: 4 months

Secondary outcomes

  1. Identify the number of patients in adjuvant treatment with tamoxifen within 4-5 years or close to end this treatment time

    Time frame: 4 months

  2. Determine the relation of positive Eg / Pg receptors vs negative (unknown) Eg / Pg receptors and the only selection criteria for the adjuvant treatment with tamoxifen is postmenopause status

    Time frame: 4 months

07

Study locations

1 site
  • Novartis Investigative Site
    Guadalajara, Zacatecas, México DF, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003 and a primary completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2005
First posted
Oct 12, 2005
Start
Feb 2003
Primary completionActual
Feb 2007
Last update
Nov 19, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00237224
First posted
Oct 12, 2005
Start date
Feb 2003
Primary completion
Feb 2007
Last update
Nov 19, 2009

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion